CBR-470-1
CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP+-induced cytotoxicity through activation of the Keap1-Nrf2 cascade[1][2].
Product Specifications
CAS Number
2416095-06-0
UNSPSC
12352005
Target
Keap1-Nrf2
Type
Reference compound
Related Pathways
NF-κB
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/cbr-470-1.html
Purity
98.02
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
CC(C)CN[C@H]([C@@H](S(=O)(C1=CC=C(Cl)C=C1)=O)C2)CS2(=O)=O
Molecular Formula
C14H20ClNO4S2
Molecular Weight
365.89
References & Citations
[1]Bollong MJ, et, al. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature. 2018 Oct;562 (7728) :600-604.|[2]Zheng J, et, al. PGK1 inhibitor CBR-470-1 protects neuronal cells from MPP+. Aging (Albany NY) . 2020 Jul 10;12 (13) :13388-13399.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1404040-01 0.5 mg (E-Coli)
Recombinant Rat Leucine-rich repeat-containing protein 4 (Lrrc4), partial
Sign In for Pricing
View Details MBS1404040-02 0.05 mg (Baculovirus)
Recombinant Rat Leucine-rich repeat-containing protein 4 (Lrrc4), partial
Sign In for Pricing
View Details